<?xml version='1.0' encoding='utf-8'?>
<document id="22913907"><sentence text="Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects."><entity charOffset="10-22" id="DDI-PubMed.22913907.s1.e0" text="cyclosporine" /><entity charOffset="50-60" id="DDI-PubMed.22913907.s1.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.22913907.s1.e0" e2="DDI-PubMed.22913907.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22913907.s1.e0" e2="DDI-PubMed.22913907.s1.e1" /></sentence><sentence text="Colchicine and cyclosporine are often administered together, particularly in patients who have undergone solid-organ transplantation"><entity charOffset="0-10" id="DDI-PubMed.22913907.s2.e0" text="Colchicine" /><entity charOffset="15-27" id="DDI-PubMed.22913907.s2.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.22913907.s2.e0" e2="DDI-PubMed.22913907.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22913907.s2.e0" e2="DDI-PubMed.22913907.s2.e1" /></sentence><sentence text=" However, the potential for drug-drug interactions between these agents resulting in colchicine toxicity is high"><entity charOffset="85-95" id="DDI-PubMed.22913907.s3.e0" text="colchicine" /></sentence><sentence text="" /><sentence text="This study sought to determine the effect of cyclosporine (100-mg capsule) on the pharmacokinetics of the US Food and Drug Administration-approved formulation of colchicine (0"><entity charOffset="45-57" id="DDI-PubMed.22913907.s5.e0" text="cyclosporine" /><entity charOffset="162-172" id="DDI-PubMed.22913907.s5.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.22913907.s5.e0" e2="DDI-PubMed.22913907.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22913907.s5.e0" e2="DDI-PubMed.22913907.s5.e1" /></sentence><sentence text="6-mg tablet) after single oral-dose administration in 24 healthy subjects under fasted conditions in a phase 1, single-sequence, 2-period drug-drug interaction trial" /><sentence text="" /><sentence text="Coadministration of cyclosporine increased colchicine maximum observed plasma concentration, area under the plasma concentration-time curve to the last measurable time point, and area under the plasma concentration-time curve to time infinity on average by 224%, 216%, and 215% (ie, almost doubled), respectively, and decreased colchicine oral clearance on average by 72% (from 48"><entity charOffset="20-32" id="DDI-PubMed.22913907.s8.e0" text="cyclosporine" /><entity charOffset="43-53" id="DDI-PubMed.22913907.s8.e1" text="colchicine" /><entity charOffset="328-338" id="DDI-PubMed.22913907.s8.e2" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.22913907.s8.e0" e2="DDI-PubMed.22913907.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22913907.s8.e0" e2="DDI-PubMed.22913907.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22913907.s8.e0" e2="DDI-PubMed.22913907.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22913907.s8.e1" e2="DDI-PubMed.22913907.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22913907.s8.e1" e2="DDI-PubMed.22913907.s8.e2" /></sentence><sentence text="24 to 13" /><sentence text="42 L/h), indicating substantially higher colchicine exposures when combined with cyclosporine, compared with colchicine alone"><entity charOffset="41-51" id="DDI-PubMed.22913907.s10.e0" text="colchicine" /><entity charOffset="81-93" id="DDI-PubMed.22913907.s10.e1" text="cyclosporine" /><entity charOffset="109-119" id="DDI-PubMed.22913907.s10.e2" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.22913907.s10.e0" e2="DDI-PubMed.22913907.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22913907.s10.e0" e2="DDI-PubMed.22913907.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22913907.s10.e0" e2="DDI-PubMed.22913907.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22913907.s10.e1" e2="DDI-PubMed.22913907.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22913907.s10.e1" e2="DDI-PubMed.22913907.s10.e2" /></sentence><sentence text="" /><sentence text="The dose of colchicine should be reduced by â‰¥ 50% when colchicine and cyclosporine are administered concurrently for treatment and prophylaxis of gout flares or treatment of patients with familial Mediterranean fever"><entity charOffset="12-22" id="DDI-PubMed.22913907.s12.e0" text="colchicine" /><entity charOffset="55-65" id="DDI-PubMed.22913907.s12.e1" text="colchicine" /><entity charOffset="70-82" id="DDI-PubMed.22913907.s12.e2" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.22913907.s12.e0" e2="DDI-PubMed.22913907.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22913907.s12.e0" e2="DDI-PubMed.22913907.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22913907.s12.e0" e2="DDI-PubMed.22913907.s12.e2" /><pair ddi="false" e1="DDI-PubMed.22913907.s12.e1" e2="DDI-PubMed.22913907.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22913907.s12.e1" e2="DDI-PubMed.22913907.s12.e2" /></sentence><sentence text=" Health care professionals should be vigilant for potential adverse events during colchicine/cyclosporine coadministration, notably in patients who have undergone solid-organ transplantation"><entity charOffset="82-92" id="DDI-PubMed.22913907.s13.e0" text="colchicine" /><entity charOffset="93-105" id="DDI-PubMed.22913907.s13.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.22913907.s13.e0" e2="DDI-PubMed.22913907.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22913907.s13.e0" e2="DDI-PubMed.22913907.s13.e1" /></sentence><sentence text="" /><sentence text="www" /><sentence text="ClinicalTrials" /><sentence text="gov identifier NCT00983931 (http://clinicaltrials" /><sentence text="gov/ct2/show/NCT00983931)" /><sentence text="" /></document>